This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O’Gorman, D. B. Articles by Scott, C. D. Search for Related Content PubMed PubMed Citation Articles by O’Gorman, D. B. Articles by Scott, C. D.

Decreased Insulin-like Growth Factor-II/Mannose 6-Phosphate Receptor Expression Enhances Tumorigenicity in JEG-3 Cells

Kolling Institute of Medical Research, University of Sydney and Royal North Shore Hospital, St. Leonards, NSW 2065, Australia

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
The insulin-like growth factor-II/mannose-6 phosphate receptor (IGF-II/M6PR) is believed to bind and degrade the potent mitogen IGF-II, a growth factor for many tumors. This receptor has been shown to be mutated and/or lost in a significant percentage of a variety of tumors, implying that it may act as a negative regulator of cell growth. In this study, we demonstrate that down-regulation of this receptor, mediated by antisense IGF-II/M6PR cDNA transfection into JEG-3 choriocarcinoma cells, results in increased growth rate in vitro and increased tumor growth rate in vivo. These findings demonstrate that a decrease in IGF-II/M6PR expression results in a growth advantage in JEG-3 cells and are consistent with the hypothesis that the IGF-II/M6PR is an inhibitor of tumor growth.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
The IGF-II/M6PR² is a monomeric glycoprotein found in two forms: a membrane-associated molecule of M_r 270,000 and a soluble receptor of M_r 220,000 as assessed by SDS-PAGE (1) . This receptor interacts with at least two distinct classes of ligand. One is the mitogen IGF-II, and the IGF-II/M6PR is believed to compete with the type-1 IGF receptor for this peptide by sequestering excess mitogen and transporting it to the lysosomes for degradation (2) . Direct evidence for this is the finding that mice lacking IGF-II/M6PR exhibit overgrowth and perinatal mortality, which can be prevented by concurrent disruption of either the IGF-II gene or the IGF-I receptor gene (3) . The second class of ligand interacting with the IGF-II/M6PR is glycoproteins bearing M6P moieties on their carbohydrate side chains. Several of these are important regulators of tumor cell growth and metastasis, including lysosomal proteases and precursor TGF-1 (1) . It has been proposed that the IGF-II/M6PR may prevent tissue overgrowth by mediating the degradation of IGF-II and the activation of TGF-1. A wide variety of tumor types have been shown to display loss of heterozygosity and mutation of IGF-II/M6PR (4) , leading to the hypothesis that the IGF-II/M6PR may be a negative regulator of tumor growth. That increased IGF-II levels and decreased active TGF-1 levels have been noted in tumors featuring IGF-II/M6PR inactivating mutations support this hypothesis (5) . To further test this hypothesis, we have transfected JEG-3, a choriocarcinoma cell line that secretes both IGF-II and TGF-1 with an antisense IGF-II/M6PR cDNA construct to determine whether reduced IGF-II/M6PR levels lead to a growth advantage for tumor cells and thus enhance their tumorigenicity.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Human IGF-II/M6PR cDNA Constructs.
Human IGF-II/M6PR cDNA (originally cloned by Dr. W. Sly, GenBank accession no. J03528) was a kind gift from Dr. Richard McDonald (University of Nebraska, Omaha, NE). Sense and antisense constructs, consisting of the nucleotides 1 to 718 of the IGF-II/M6PR cDNA, were subcloned into pBLUESCRIPT SK+ (Stratagene) as a HindIII fragment in both orientations. The sense and antisense IGF-II/M6P receptor cDNA constructs were then cloned into the KpnI and XbaI sites of pOP13 MCS2, which allows transcription from the Rous sarcoma virus promoter. The vector pOP13 MCS2, a derivative of the LacSwitch vector (Stratagene) pOP13CAT, was generated by replacing the chloramphenicol acetyltransferase gene with the multiple cloning sites XbaI, BglII, SmaI, ClaI, KpnI, and XhoI. Stable transfection of JEG-3 cells (American Type Culture Collection, Rockville, MD), cultured in MEM with 10% FCS, was performed using Fugene 6 transfection reagent (Boehringer Mannheim), and transfectants were selected for Geneticin resistance (G418) at 400 µg/ml. Clonal foci were isolated, grown under selection, screened for soluble IGF-II/M6PR expression using a specific ELISA (6) , which was corrected for cell number by total DNA concentration (7) .

In Vitro Growth Rate.
Transfected JEG-3 clones were plated at 1 x 10⁴ cells/ml in 24-well trays (MEM with 10% FCS). Cells were trypsinized and counted each day using a hemocytometer for 4 days after plating. Each experiment was performed in quadruplicate and repeated at least three times.

Tumor Growth in Vivo.
JEG-3 clones were harvested by trypsinization, washed, and resuspended at 1 x 10⁷ viable cells/ml in MEM medium with 0.2% BSA. Viability was assessed by trypan blue exclusion and was routinely >90%. Cells (1 x 10⁶ cells in 100 µl) were injected s.c. at the dorsal neck into four groups (two sense and two antisense IGF-II/M6PR cDNA transfected cell lines) of eight athymic nu/nu female mice. Results were pooled from four separate experiments. Tumor growth is rapid in this protocol, and each experiment was terminated at a single time point when the largest tumors were 1 cm in diameter (10–12 days after injection). Postmortem blood samples were taken from all test animals. Tumors were paraffin embedded and stained with H&E for histology. The experiments were repeated four times and carried out with approval of the Institutional Animal Care and Ethics Committee.

	Results

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
JEG-3 choriocarcinoma cells stably transfected with either an antisense cDNA construct or a sense cDNA construct were assessed for IGF-II/M6PR mRNA and protein expression by Northern blot analysis and receptor ELISA, respectively. Although no significant difference in mRNA levels were detected between antisense and sense IGF-II/M6PR cDNA transfectants (data not shown), soluble IGF-II/M6PR protein levels in conditioned medium were decreased in the majority of antisense cDNA transfectants (Fig. 1) . Antisense IGF-II/M6PR cDNA transfected clones also displayed a marked decrease in intracellular IGF-II/M6PR levels when assessed by immunohistochemistry (data not shown). Clones AS/8, AS/10, AS/12, and AS/13, which exhibited >50% decrease in soluble IGF-II/M6PR expression (Fig. 1) , were chosen for further study.

View larger version (35K): [in this window] [in a new window]   Fig. 1. Quantitation of soluble IGF-II/M6PR in 24-h conditioned media by ELISA. Cells were grown to confluence in complete media and washed in serum-free media for 8 h. Conditioned media were then collected after 24 h from vector transfected (V), sense IGF-II/M6PR cDNA transfected (S), and antisense IGF-II/M6PR cDNA transfected (AS) clones. Each clone was assayed in duplicate and corrected for DNA concentration. Results are expressed as a percentage relative to vector-transfected cells.

View larger version (21K): [in this window] [in a new window]   Fig. 2. In vitro growth rate of antisense IGF-II/M6PR cDNA transfected JEG-3 cells. Cells were plated at 1 x 104/well in MEM containing 10% FCS on day 1, and total cell numbers were determined daily for 4 days. Values shown are means of quadruplicate wells from three separate experiments; bars, SD. Comparisons of pooled (S1 and S5) to antisense (AS) IGF-II/M6PR cDNA transfected cells by repeated measures ANOVA, AS/8 (P = 0.60); AS/10 (P = 0.05); AS/12 (P = 0.62); AS/13 (P < 0.01) are shown. When assessed as a group, the growth rates of the sense controls were significantly lower than the antisense cells (P = 0.02). , S; , AS/8; , AS/10; •, AS/12; , AS/13.

View larger version (23K): [in this window] [in a new window]   Fig. 3. In vivo growth of JEG-3 cells is enhanced by transfection with antisense IGF-II/M6PR cDNA. Tumor growth from antisense (AS) and pooled (S1 and S5) IGF-II/M6PR cDNA transfected cells was compared in nu/nu mice as described in "Materials and Methods." Pooled data from four experiments are shown as means of wet tumor weights of all animals with visible tumors; bars, SE. Compared with tumors derived from sense IGF-II/M6PR cDNA controls (n = 35), tumors from antisense cDNA transfected cells were significantly larger, AS/10 (P = 0.025; n = 29) and AS/13 (P = 0.030; n = 29), as assessed by one-way ANOVA.

	Discussion

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

JEG-3 choriocarcinoma cells, like their trophoblastic precursors, express both IGF receptors, the type 1 IGF receptor (11) , and the IGF-II/M6PR (12) . Because JEG-3 cells express IGF-II but not IGF-I mRNA (13 , 14) , it is probable that these cells undergo autocrine growth stimulation from endogenous IGF-II via their type 1 IGF receptors, a feature of several tumor cell lines (15) . JEG-3 cells also express TGF-1 but are insensitive to the growth-inhibitory effects of this cytokine (9) . These characteristics make the JEG-3 cell line useful for examining the effects of altered IGF-II/M6PR expression in the absence of confounding effects of TGF-1 on growth rate.

In this study, we demonstrate that antisense cDNA-mediated decrease in endogenous IGF-II/M6PR results in an increase in the growth rate of JEG-3 choriocarcinoma cells in vitro. Because this receptor is believed to sequester and degrade IGF-II (2) , a decrease in IGF-II/M6PR could potentially result in decreased degradation and hence increased bioavailability of IGF-II to the type 1 IGF receptor. Because the IGF-II/M6PR has been shown to be an integral part of the activation of precursor TGF-1 to TGF-1 (16) , a reduction in IGF-II/M6PR availability could also result in a decrease in TGF-1 activation. However, because JEG-3 cells are insensitive to the growth-inhibitory effects of TGF-1 (9) , any alteration in TGF-1 processing should not affect proliferation in this system.

Antisense IGF-II/M6PR cDNA transfected JEG-3 clones form significantly larger tumors when injected into nude mice. The percentage of animals that developed tumors after injection with the antisense IGF-II/M6PR cDNA transfected cells was also significantly higher than those injected with sense IGF-II/M6PR cDNA transfected cells, suggesting that not only the growth rate but also the tumorigenicity of the antisense IGF-II/M6PR cDNA transfected cells is increased. These tumors retain decreased IGF-II/M6PR expression in vivo, as shown by an overall decrease in soluble human IGF-II/M6PR levels in the mouse sera compared with sera taken from animals with sense IGF-II/M6PR cDNA-derived tumors. Although the mechanisms involved in the increased tumor growth rate are not characterized yet, there are several likely candidates. An increase in IGF-II bioavailability to type 1 IGF receptors is the most obvious. The IGF-II/M6PR is also known to be involved in the transport of lysosomal proteases, and mouse lines deficient in IGF-II/M6PR display decreased lysosomal storage and a corresponding increase in lysosomal enzyme secretion (17) . The antisense cDNA transfected clones may therefore secrete more lysosomal proteases than the controls cells, and this could result in increased extracellular matrix degradation and subsequently increase the invasion rate of the tumor cells. The IGF-II/M6PR has been implicated in the specific degradation of the uPAR; therefore, a decrease in IGF-II/M6PR expression may result in an increase in cell surface concentrations of this receptor (18) . Increased uPAR expression has been shown to be associated with increased cellular adhesion and tumor cell migration both in vivo and in vitro (19) ; therefore, this decrease in uPAR degradation may lead to increased cellular adhesion and invasion. A combination of all of these mechanisms may be responsible for the marked increase in tumor growth demonstrated in this study, and future work will focus on examination of the JEG-3 sense and antisense IGF-II/M6PR cDNA transfected cell lines and tumors to identify genes whose expression has been regulated by the altered IGF-II/M6PR levels. The results reported here support the hypothesis that the IGF-II/M6PR may act as a negative regulator of cell growth and that reduction of its expression leads to enhanced tumorigenicity.

	ACKNOWLEDGMENTS

 
We thank the Department of Anatomical Pathology, specifically Dr. Jeanette Philips, for assessing the histopathology of the tumors, Sue Smith for embedding and sectioning of the tumor tissues, and Stella Panaretos for technical assistance.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed.

² The abbreviations used are: IGF-II/M6PR, insulin-like growth factor-II/mannose 6-phosphate receptor; TGF, transforming growth factor; uPAR, urokinase plasminogen activator receptor.

Received 8/ 2/99. Accepted 10/ 5/99.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 

1. Nissley P., Kiess W., Sklar M. M. The insulin-like growth factor-II/mannose 6-phosphate receptor Roith D. Le eds. . Insulin-Like Growth Factors: Molecular and Cellular Aspects, : 111-150, CRC Press Boca Raton, FL 1991.
2. Polychronakos C., Guyda H. J., Janthly U., Posner B. I. Effects of mannose-6-phosphate on receptor-mediated endocytosis of insulin-like growth factor-II. Endocrinology, 127: 1861-1866, 1990.[Abstract]
3. Ludwig T., Eggenschwiler J., Fisher P., D’Ercole A. J., Davenport M. L., Efstratiadis A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev. Biol., 177: 517-535, 1996.[Medline]
4. Ouyang H., Shiwaku H. O., Hagiwara H., Miura K., Abe T., Kato Y., Ohtani H., Shiiba K., Souza R. F., Meltzer S. J., Horii A. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. Cancer Res., 57: 1851-1854, 1997.[Abstract/Free Full Text]
5. Wang S., Souza R. F., Kong D., Yin J., Smolinski K. N., Zou T. T., Frank T., Young J., Flanders K. C., Sugimura H., Abraham J. M., Meltzer S. J. Deficient transforming growth factor-1 activation and excessive insulin-like growth factor II (IGFII) expression in IGFII receptor-mutant tumors. Cancer Res., 57: 2543-2546, 1997.[Abstract/Free Full Text]
6. Costello M., Baxter R. C., Scott C. D. Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum: measurement by enzyme-linked immunosorbent assay. J. Clin. Endocrinol. Metab., 84: 611-617, 1999.[Abstract/Free Full Text]
7. Cesarone C. F., Bolognesi C., Santi L. Improved microfluorometric DNA determination in biological material using 33258 Hoechst. Anal. Biochem., 100: 188-197, 1979.[Medline]
8. Giudice L. C. Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine. Fertil. Steril., 61: 1-17, 1994.[Medline]
9. Graham C. H., Lala P. K. Mechanisms of placental invasion of the uterus and their control. Biochem. Cell Biol., 70: 867-874, 1992.[Medline]
10. Ohlsson R., Holmgren L., Glaser A., Szpecht A., Pfeifer-Ohlsson S. Insulin-like growth factor 2 and short-range stimulatory loops in control of human placental growth. EMBO J., 8: 1993-1999, 1989.[Medline]
11. Ritvos O., Rutanen E. M., Pekonen F., Jalkanen J., Suikkari A. M., Ranta T. Characterization of functional type I insulin-like growth factor receptors from human choriocarcinoma cells. Endocrinology, 122: 395-401, 1988.[Abstract]
12. MacDonald R. G. Mannose-6-phosphate enhances cross-linking efficiency between insulin-like growth factor-II (IGF-II) and IGF-II/mannose-6-phosphate receptors in membranes. Endocrinology, 128: 413-421, 1991.[Abstract]
13. Ritvos O., Ranta T., Jalkanen J., Suikkari A. M., Voutilainen R., Bohn H., Rutanen E. M. Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology, 122: 2150-2157, 1988.[Abstract]
14. Fagin J. A., Pixley S., Slanina S., Ong J., Melmed S. Insulin-like growth factor I gene expression in GH3 rat pituitary cells: messenger ribonucleic acid content, immunocytochemistry, and secretion. Endocrinology, 120: 2037-2043, 1987.[Abstract]
15. Daughaday W. H. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology, 127: 1-4, 1990.[Medline]
16. Dennis P. A., Rifkin D. B. Cellular activation of latent transforming growth factor requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc. Natl. Acad. Sci. USA, 88: 580-584, 1991.[Abstract/Free Full Text]
17. Sohar I., Sleat D., Liu C. G., Ludwig T., Lobel P. Mouse mutants lacking the cation-independent mannose 6-phosphate/insulin-like growth factor II receptor are impaired in lysosomal enzyme transport: comparison of cation-independent and cation-dependent mannose 6-phosphate receptor-deficient mice. Biochem. J., 330: 903-908, 1998.
18. Nykjaer A., Christensen E. I., Vorum H., Hager H., Petersen C. M., Roigaard H., Min H. Y., Vilhardt F., Moller L. B., Kornfeld S., Gliemann J. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J. Cell Biol., 141: 815-828, 1998.[Abstract/Free Full Text]
19. Tryggvason K., Hoyhtya M., Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta, 907: 191-217, 1987.[Medline]

This article has been cited by other articles:

				L.E. Diaz, Y-C. Chuan, M. Lewitt, L. Fernandez-Perez, S. Carrasco-Rodriguez, M. Sanchez-Gomez, and A. Flores-Morales IGF-II regulates metastatic properties of choriocarcinoma cells through the activation of the insulin receptor Mol. Hum. Reprod., August 1, 2007; 13(8): 567 - 576. [Abstract] [Full Text] [PDF]

				T. L. Wise and D. D. Pravtcheva Delayed Onset of Igf2-Induced Mammary Tumors in Igf2r Transgenic Mice Cancer Res., February 1, 2006; 66(3): 1327 - 1336. [Abstract] [Full Text] [PDF]

				C Gicquel, J Weiss, J Amiel, V Gaston, Y Le Bouc, and C D Scott Epigenetic abnormalities of the mannose-6-phosphate/IGF2 receptor gene are uncommon in human overgrowth syndromes J. Med. Genet., January 1, 2004; 41(1): e4 - 4. [Full Text] [PDF]

				M. N. Szentirmay, H.-X. Yang, S. A. Pawar, C. Vinson, and M. Sawadogo The IGF2 Receptor Is a USF2-specific Target in Nontumorigenic Mammary Epithelial Cells but Not in Breast Cancer Cells J. Biol. Chem., September 26, 2003; 278(39): 37231 - 37240. [Abstract] [Full Text] [PDF]

				J. L. Kreiling, J. C. Byrd, R. J. Deisz, I. F. Mizukami, R. F. Todd III, and R. G. MacDonald Binding of Urokinase-type Plasminogen Activator Receptor (uPAR) to the Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor: CONTRASTING INTERACTIONS OF FULL-LENGTH AND SOLUBLE FORMS OF uPAR J. Biol. Chem., May 30, 2003; 278(23): 20628 - 20637. [Abstract] [Full Text] [PDF]

				B. S. Schaffer, M.-F. Lin, J. C. Byrd, J. H. Y. Park, and R. G. MacDonald Opposing Roles for the Insulin-Like Growth Factor (IGF)-II and Mannose 6-Phosphate (Man-6-P) Binding Activities of the IGF-II/Man-6-P Receptor in the Growth of Prostate Cancer Cells Endocrinology, March 1, 2003; 144(3): 955 - 966. [Abstract] [Full Text] [PDF]

				A. A. Wylie, D. J. Pulford, A. J. McVie-Wylie, R. A. Waterland, H. K. Evans, Y.-T. Chen, C. M. Nolan, T. C. Orton, and R. L. Jirtle Tissue-Specific Inactivation of Murine M6P/IGF2R Am. J. Pathol., January 1, 2003; 162(1): 321 - 328. [Abstract] [Full Text] [PDF]

				D. B. O'Gorman, J. Weiss, A. Hettiaratchi, S. M. Firth, and C. D. Scott Insulin-Like Growth Factor-II/Mannose 6-Phosphate Receptor Overexpression Reduces Growth of Choriocarcinoma Cells in Vitro and in Vivo Endocrinology, November 1, 2002; 143(11): 4287 - 4294. [Abstract] [Full Text] [PDF]

				K. R. Kalli, O. I. Falowo, L. K. Bale, M. A. Zschunke, P. C. Roche, and C. A. Conover Functional Insulin Receptors on Human Epithelial Ovarian Carcinoma Cells: Implications for IGF-II Mitogenic Signaling Endocrinology, September 1, 2002; 143(9): 3259 - 3267. [Abstract] [Full Text] [PDF]

				H. Yu and T. Rohan Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489. [Abstract] [Full Text] [PDF]

				H. M. Khandwala, I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth Endocr. Rev., June 1, 2000; 21(3): 215 - 244. [Abstract] [Full Text]

				J. Linnell, G. Groeger, and A. B. Hassan Real Time Kinetics of Insulin-like Growth Factor II (IGF-II) Interaction with the IGF-II/Mannose 6-Phosphate Receptor. THE EFFECTS OF DOMAIN 13 AND pH J. Biol. Chem., June 22, 2001; 276(26): 23986 - 23991. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O’Gorman, D. B. Articles by Scott, C. D. Search for Related Content PubMed PubMed Citation Articles by O’Gorman, D. B. Articles by Scott, C. D.